Camson Bio Technologies Limited reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2015. For the quarter, on standalone basis, the company reported total income from operations of INR 45.455 million compared to INR 545.851 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 84.950 million compared to profit of INR 42.041 million a year ago. Loss from ordinary activities before tax was INR 96.953 million compared to profit of INR 37.971 million a year ago. Net loss for the period was INR 101.391 million or INR 3.38 per diluted share before and after extraordinary items compared to net profit of INR 19.553 million or INR 0.65 per diluted share and after extraordinary items a year ago.

For the nine months, on standalone basis, the company reported total income from operations of INR 310.378 million compared to INR 1,318.846 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 80.535 million compared to profit of INR 93.407 million a year ago. Loss from ordinary activities before tax was INR 101.366 million compared to profit of INR 73.338 million a year ago. Net loss for the period was INR 108.196 million or INR 3.61 per diluted share before and after extraordinary items compared to net profit of INR 62.270 million or INR 2.08 per diluted share before and after extraordinary items a year ago.